A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99) (ACCURATE)
Primary Purpose
Renal Tumor, Renal Cancer
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Robot assisted partial nephrectomy with 3D image guidance
Sponsored by
About this trial
This is an interventional treatment trial for Renal Tumor focused on measuring image guidance, augmented reality, robotics
Eligibility Criteria
Inclusion Criteria:
- Patients over 18 years
- Indication of RAPN for suspicious renal tumor
- Moderate or high complexity renal tumor (RENAL Nephrometry Score (NS) >7)
- Da Vinci® surgical system available for the surgery
- Patient affiliated to the French social security system or an equivalent system
- Signed informed consent form UroCCR and ACCURATE
Exclusion Criteria:
- Medical contraindication to RAPN
- Renal insufficiency forbidding iodine injection
- Patient with allergy to iodinated contrast products
- Patient concerned by articles L1121-5 to 8 of the French public health code (protected persons)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
conventional group
3D IGRAPN GROUP
Arm Description
Robot-Assisted Partial Nephrectomy without 3D navigation
Robot-Assisted Partial Nephrectomy with 3D navigation
Outcomes
Primary Outcome Measures
TRIFECTA score
evaluating peri-operative outcome complications as well as oncological safety and long-term renal function preservation.
Secondary Outcome Measures
Recurrence free survival
Recurrence-free survival and Overall survival
Overall survival
Overall Survival
Number of Conversion to radical nephrectomy
Need to convert to radical nephrectomy for intra-operative reasons
rate of Off clamp or superselective ischemia
use of techniques without renal artery clamping
Amount of parenchyma preserved (according to CT scan)
Preservation of safe kidney
Blood loss
Blood loss
NASA TLX
Ergonomy score (questionnaire completed at the end of the procedure by the surgeon)
Warm ischemia time
Warm ischemia time
Medico-economic evaluation
ncremental cost-utility ratio (ICUR) expressed as the extra cost per a QALY gained by the 3D-IGRAPN strategy compared to standard RAPN.
Full Information
NCT ID
NCT05572216
First Posted
October 5, 2022
Last Updated
October 6, 2022
Sponsor
University Hospital, Grenoble
1. Study Identification
Unique Protocol Identification Number
NCT05572216
Brief Title
A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)
Acronym
ACCURATE
Official Title
A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 2022 (Anticipated)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
November 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goal of this clinical trial is to evaluate peri and post-operative outcomes as well as long-term survival of 3D IGRAPN compared to conventional Robot-Assisted Partial Nephrectomy (RAPN) for moderate and highly complex renal tumors.
The main questions aim to answer:
peri-operative complications
oncological safety
long term renal function Participants will be asked to do undergo 3D-IGRAPN. Researchers will compare 3D-IGRAPN to RAPN to see if peri-operative outcomes are better in the experimental group.
Detailed Description
Robot-assisted partial nephrectomy (RAPN) is the standard treatment for localized kidney tumors. New 3D modeling and reconstruction technologies have enabled the development of real time imageguided surgery using virtual reality (VR). In view of advances in artificial intelligence and surface recognition based on deep-learning, augmented reality (AR) by merging a 3D reconstructed virtual image onto the real per-operative view represents the next step in image-guided surgery.
3D IG-RAPN using Synapse 3D (Fujifilm) and DaVinci Tile-Pro display (Intuitive Surgical) vs conventional RAPN without 3D navigation in 12 high-volume urological centers from the UroCCR Network.
Outcoume : Primary endpoint is a composite validated score (TRIFECTA) evaluating peri-operative complications as well as oncological safety and long-term renal function preservation. Secondary endpoints assess long-term survival, ergonomics and surgeon satisfaction. A medico-economic evaluation will be performed.
Methodology: ACCURATE is a nation-wide, single-blind, multicentric, prospective randomized controlled trial enrolling 694 patients with a single complex renal mass, defined as RENAL NS≥7.
Randomization (1:1) between the experimental and the conventional group will take place on day of inclusion and will be stratified by center.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Tumor, Renal Cancer
Keywords
image guidance, augmented reality, robotics
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
ACCURATE is a nation-wide, single-blind, multicentric, prospective randomized controlled trial enrolling patients with a single complex renal mass, defined as RENAL NS≥7. Randomization (1:1) between the experimental and the conventional group will take place on day of inclusion and will be stratified by center.
Masking
Participant
Masking Description
single blind
Allocation
Randomized
Enrollment
694 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
conventional group
Arm Type
No Intervention
Arm Description
Robot-Assisted Partial Nephrectomy without 3D navigation
Arm Title
3D IGRAPN GROUP
Arm Type
Experimental
Arm Description
Robot-Assisted Partial Nephrectomy with 3D navigation
Intervention Type
Procedure
Intervention Name(s)
Robot assisted partial nephrectomy with 3D image guidance
Other Intervention Name(s)
without 3D image guidance
Intervention Description
patient have a partial nephrectomy for renal complex tumor
Primary Outcome Measure Information:
Title
TRIFECTA score
Description
evaluating peri-operative outcome complications as well as oncological safety and long-term renal function preservation.
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Recurrence free survival
Description
Recurrence-free survival and Overall survival
Time Frame
2 and 5 years
Title
Overall survival
Description
Overall Survival
Time Frame
2 and 5 years
Title
Number of Conversion to radical nephrectomy
Description
Need to convert to radical nephrectomy for intra-operative reasons
Time Frame
Intraopertively
Title
rate of Off clamp or superselective ischemia
Description
use of techniques without renal artery clamping
Time Frame
Intraoperatively
Title
Amount of parenchyma preserved (according to CT scan)
Description
Preservation of safe kidney
Time Frame
Month 6
Title
Blood loss
Description
Blood loss
Time Frame
Intra-operatively
Title
NASA TLX
Description
Ergonomy score (questionnaire completed at the end of the procedure by the surgeon)
Time Frame
at the end of the surgery
Title
Warm ischemia time
Description
Warm ischemia time
Time Frame
Intra-operatively
Title
Medico-economic evaluation
Description
ncremental cost-utility ratio (ICUR) expressed as the extra cost per a QALY gained by the 3D-IGRAPN strategy compared to standard RAPN.
Time Frame
Month 1 and 6
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients over 18 years
Indication of RAPN for suspicious renal tumor
Moderate or high complexity renal tumor (RENAL Nephrometry Score (NS) >7)
Da Vinci® surgical system available for the surgery
Patient affiliated to the French social security system or an equivalent system
Signed informed consent form UroCCR and ACCURATE
Exclusion Criteria:
Medical contraindication to RAPN
Renal insufficiency forbidding iodine injection
Patient with allergy to iodinated contrast products
Patient concerned by articles L1121-5 to 8 of the French public health code (protected persons)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Alexandre LONG, Pr
Phone
0476767642
Ext
+33
Email
jalong@chu-grenoble.fr
First Name & Middle Initial & Last Name or Official Title & Degree
ASSILAH BOUZIT
Phone
0476767971
Ext
+33
Email
abouzit@chu-grenoble.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Alexandre LONG, Pr
Organizational Affiliation
University Hospital, Grenoble
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33811291
Citation
Michiels C, Khene ZE, Prudhomme T, Boulenger de Hauteclocque A, Cornelis FH, Percot M, Simeon H, Dupitout L, Bensadoun H, Capon G, Alezra E, Estrade V, Bladou F, Robert G, Ferriere JM, Grenier N, Doumerc N, Bensalah K, Bernhard JC. 3D-Image guided robotic-assisted partial nephrectomy: a multi-institutional propensity score-matched analysis (UroCCR study 51). World J Urol. 2023 Feb;41(2):303-313. doi: 10.1007/s00345-021-03645-1. Epub 2021 Apr 2.
Results Reference
result
PubMed Identifier
31898992
Citation
Porpiglia F, Checcucci E, Amparore D, Piramide F, Volpi G, Granato S, Verri P, Manfredi M, Bellin A, Piazzolla P, Autorino R, Morra I, Fiori C, Mottrie A. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA >/=10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. 2020 Aug;78(2):229-238. doi: 10.1016/j.eururo.2019.11.024. Epub 2019 Dec 30.
Results Reference
result
PubMed Identifier
33931361
Citation
Long JA, Fiard G, Giai J, Teyssier Y, Fontanell A, Overs C, Poncet D, Descotes JL, Rambeaud JJ, Moreau-Gaudry A, Ittobane T, Bouzit A, Bosson JL, Lanchon C. Superselective Ischemia in Robotic Partial Nephrectomy Does Not Provide Better Long-term Renal Function than Renal Artery Clamping in a Randomized Controlled Trial (EMERALD): Should We Take the Risk? Eur Urol Focus. 2022 May;8(3):769-776. doi: 10.1016/j.euf.2021.04.009. Epub 2021 Apr 27.
Results Reference
result
Learn more about this trial
A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)
We'll reach out to this number within 24 hrs